Skip to main content
      #2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger diseas

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger disease flares. But methotrexate use and older age significantly blunted antibody responses ➡️key factors to consider for vaccine strategies in RA. @RheumNow #ACR25
      kids w
      👇
      Undifferentiated #systemic #autoinflammatory #disease

      Rx #IL1i

      N=33
      =boys &girls 3.5 yrs Sx

      Abst#2

      Janet Pope Janetbirdope

      4 months 1 week ago
      kids w 👇 Undifferentiated #systemic #autoinflammatory #disease Rx #IL1i N=33 =boys &girls 3.5 yrs Sx Abst#2151 #ACR25 @ACRheum @RheumNow There are many periodic fever syndromes 🤔some mutations are not yet discovered Access to &use of Anakinra canukinumab Rilonacept https://t.co/IyTx0nFxKC
      #2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, w

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25
      #ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS
      Abstract 2697: Compared to MMF, tacrolimus showed
      - similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29)

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Abstract 2697: Compared to MMF, tacrolimus showed - similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29) - similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35) - serious AEs less frequent (12.3% vs. 30.8%) @RheumNow #ACR25 https://t.co/o3LtgOp7St
      In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressu

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressure. PsA outcomes improved proportionally with weight loss. Regression analyses revealed that each 1% reduction in body weight was associated with significant https://t.co/Pph1PjfOve
      Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed:
      - rapid depletion of CD19 B cells w/ recovery by

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed: - rapid depletion of CD19 B cells w/ recovery by Day 90 - Days 180 and 360: returning B cells largely naive (CD27-IgD+) - Interferon expression ↓ after CAR T treatment @RheumNow #ACR25 https://t.co/FzdFbqWwtE
      #ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed si

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW
      #2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25
      Abstract 2695: Deep dive into B-cell depletion (BCD)
      Lymph node biopsy pre/post tx:
      🔹 CAR T: complete BCD + disrupted

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Abstract 2695: Deep dive into B-cell depletion (BCD) Lymph node biopsy pre/post tx: 🔹 CAR T: complete BCD + disrupted follicular architecture 🔹 RTX, OBI, BLIN: reduced BCD + preserved follicular architecture ✅ Complete LN depletion → drug-free remission @RheumNow #ACR25
      Inflammation skews lipid levels in RA: the “lipid paradox”

      Using data from CERTAIN and VARA, inflammation (hsCRP)-

      Jiha Lee JihaRheum

      4 months 1 week ago
      Inflammation skews lipid levels in RA: the “lipid paradox” Using data from CERTAIN and VARA, inflammation (hsCRP)-adjusted TC & LDL better predicted ASCVD events than standard lipids. Are we missing RA pts who need statins? @RheumNow #ACR25 A#2681
      #2681 Tackling the “lipid paradox” in RA: inflammation-adjusted TC & LDL (using hsCRP correction) improved ASCVD

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #2681 Tackling the “lipid paradox” in RA: inflammation-adjusted TC & LDL (using hsCRP correction) improved ASCVD risk prediction and flagged more high-risk patients than standard lipids. A smarter way to guide statin use in RA. @RheumNow #ACR25
      Abst 2694:
      Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction
      🔹 P

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS
      In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor a

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657
      Lots of interest in MRI for GCA diagnosis... but what about monitoring?

      Case series of 14 pts: MRI identified relapse p

      Mike Putman EBRheum

      4 months 1 week ago
      Lots of interest in MRI for GCA diagnosis... but what about monitoring? Case series of 14 pts: MRI identified relapse prior to symptoms or inflammatory markers in 2 cases, including those on TCZ, which hides them More available in US context, noninvasive, & more structures https://t.co/pnrI9SEpll
      ×